Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Nocardia infection in lung transplant recipients

View through CrossRef
Abstract:  Nocardia is a well‐recognized pathogen in immunocompromised hosts, but the incidence of Nocardia infections in lung transplant recipients is not well defined. A chart review from 1990 to 2007 at Clarian Hospital Lung Transplant Center and Indiana University Medical Center revealed Nocardia infections in four of 410 lung transplant recipients despite prophylaxis. All infections were confined to lung and occurred at a median time of 315 d after transplantation. Nocardia nova was isolated in two patients, Nocardia farcinica in one, and unspecified Nocardia sp. in one. Nocardia isolates were susceptible to trimethoprim sulfa (TMP/SMX). Our data suggest that the dose of TMP/SMX, commonly used for Pneumocystis prophylaxis is not protective for Nocardia. Contrary to historic data reporting 40% mortality, none of the patients in our study died because of Nocardia. Nocardia infection is an under‐recognized entity in lung transplant recipients, and the optimal duration of therapy and prophylaxis are unclear.
Title: Nocardia infection in lung transplant recipients
Description:
Abstract:  Nocardia is a well‐recognized pathogen in immunocompromised hosts, but the incidence of Nocardia infections in lung transplant recipients is not well defined.
A chart review from 1990 to 2007 at Clarian Hospital Lung Transplant Center and Indiana University Medical Center revealed Nocardia infections in four of 410 lung transplant recipients despite prophylaxis.
All infections were confined to lung and occurred at a median time of 315 d after transplantation.
Nocardia nova was isolated in two patients, Nocardia farcinica in one, and unspecified Nocardia sp.
in one.
Nocardia isolates were susceptible to trimethoprim sulfa (TMP/SMX).
Our data suggest that the dose of TMP/SMX, commonly used for Pneumocystis prophylaxis is not protective for Nocardia.
Contrary to historic data reporting 40% mortality, none of the patients in our study died because of Nocardia.
Nocardia infection is an under‐recognized entity in lung transplant recipients, and the optimal duration of therapy and prophylaxis are unclear.

Related Results

2710. Long Term Use of Contezolid in Lung Transplant Recipients Infected with Nocardia Species
2710. Long Term Use of Contezolid in Lung Transplant Recipients Infected with Nocardia Species
Abstract Background Nocardia commonly infects lung transplant recipients (LTR). Current oral options for long-term therapy may r...
Hepatitis E Viraemia in Transplant Recipients
Hepatitis E Viraemia in Transplant Recipients
Abstract Introduction: Hepatitis E Virus (HEV) is one of the leading causes of acute infectious hepatitis worldwide; while usually a s...
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
BackgroundA clinical dilemma exists in patients with CKD, ESKD, and after kidney transplantation, as they face concurrent risks of both thromboembolic and hemorrhagic complications...
P1796FACTORS PREDICTING SUBCUTANEOUS INSULIN REQUIREMENT AFTER KIDNEY TRANSPLANT
P1796FACTORS PREDICTING SUBCUTANEOUS INSULIN REQUIREMENT AFTER KIDNEY TRANSPLANT
Abstract Background and Aims Diabetes is the most common cause for end stage renal disease leading to kidney transplant. Post tr...
Microbiota and Immune Regulation in Lung Transplantation
Microbiota and Immune Regulation in Lung Transplantation
Abstract Purpose of the Review The lung and gut microbiomes have been associated with many important patient-centered out...
The humoral immune response to the BNT 162B2 vaccine in pediatrics on renal replacement therapy
The humoral immune response to the BNT 162B2 vaccine in pediatrics on renal replacement therapy
AbstractIntroductionSince the start of the COVID‐19 pandemic, data published on the immunogenicity of the SARS‐CoV‐2 BNT 162B2 vaccine in pediatric patients receiving renal replace...

Back to Top